Evidence map›GLP-1 receptor agonists × glycemic control›PMID 18201212›Full record

Trial reportDiabetic medicine : a journal of the British Diabetic Association2008

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

T Vilsbøll, B Brock, H Perrild, K Levin, H-H Lervang, K Kølendorf, T Krarup, O Schmitz, M Zdravkovic, T Le-Thi and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2008. The graph read 4 numbers from its abstract, feeding 1 cell of the map, but none could be read as for or against, so it casts no vote. It reports registered trial NCT00154401. Cited by 68 papers, 3 of them syntheses that pooled it.

4numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
30.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

Read, but not usablea number the graph found but could not read as for or against

First-phase insulin secretion1.9 mg/day liraglutide vs placebodirection of benefit for this outcome is not defined · t2dfeeds one cell of the map
Δ 103< 0.05
RESULTS: The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05).
FeedsGLP-1 receptor agonists×glycemic control
Arginine-stimulated insulin secretion1.9 mg/day liraglutide vs placebodirection of benefit for this outcome is not defined · t2dfeeds one cell of the map
Δ 94.0< 0.05
Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05).
FeedsGLP-1 receptor agonists×glycemic control
Arginine-stimulated insulin secretion1.25 mg/day liraglutide vs placebodirection of benefit for this outcome is not defined · t2dfeeds one cell of the map
Δ 114< 0.05
Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05).
FeedsGLP-1 receptor agonists×glycemic control
First-phase insulin secretion1.25 mg/day liraglutide vs placebodirection of benefit for this outcome is not defined · t2dfeeds one cell of the map
Δ 118< 0.05
RESULTS: The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05).
FeedsGLP-1 receptor agonists×glycemic control

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×glycemic control

No readable resultOpen on the map →What to test next →

40 readable studies in this cell: 96 favour the treatment, 17 find no difference, 10 favour the comparator.

Belief with this paper
0.91replicated · 68 families support, 7 contradict · against placebo
Without itNot a counted family in this claim, so removing it changes nothing.
← favours the treatmentfavours the comparator →
0 · no effect
NCT017204463,297 enrolled · 2013
Δ -0.66-0.80 to -0.52
NCT036893742,274 enrolled · 2018
Δ -0.29-0.38 to -0.20
NCT039879191,879 enrolled · 2019
Δ -0.51-0.64 to -0.38
NCT026078651,864 enrolled · 2016
Δ -0.50-0.60 to -0.40
NCT013360231,663 enrolled · 2011
Treatment contrast -0.64-0.75 to -0.53
NCT040178321,441 enrolled · 2019
Δ -0.20-0.30 to -0.10
NCT018365231,398 enrolled · 2013
Δ -0.20-0.32 to -0.07
NCT019301881,231 enrolled · 2013
Δ -1.06-1.21 to -0.91
NCT007344741,202 enrolled · 2008
Δ -0.71-0.87 to -0.55
NCT020581471,170 enrolled · 2014
Δ -0.29-0.38 to -0.19
NCT003184611,091 enrolled · 2006
Δ -1.09-1.30 to -0.88
NCT021289321,089 enrolled · 2014
Δ -0.81-0.96 to -0.67

This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.

4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00154401 phase2completed

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.

Ran2005Enrolled177Registered outcomes4Posted comparisons0ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide
PMID 19183322PMID 25504028PMID 17372153PMID 18435773other papers from this trial
Open the trial in the graph
5 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Glucagon-like peptide analogues for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2011 · on this map
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.British journal of clinical pharmacology · 2009 · on this map
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists.International journal of molecular sciences · 2025
    Review
  14. Review
  15. Article
  16. Efficacy and Safety of a Biosimilar Liraglutide (MelitideDiabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function.Handbook of experimental pharmacology · 2022
    Review

8 more citing papers are in PubMed but not listed here.

6 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

7 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

T VilsbøllDepartment of Internal Medicine F, Gentofte Hospital, Gentofte, Denmark. t.vilsboll@dadlnet.dk
B Brock
H Perrild
K Levin
H-H Lervang
K Kølendorf
T Krarup
O Schmitz
M Zdravkovic
T Le-Thi
S Madsbad
Gentofte Hospital · DKBispebjerg Hospital · DKNovo Nordisk (India) · INAalborg University Hospital · DKHvidovre Hospital · DKRoskilde Sygehus · DK

Funding

No grant is acknowledged in the PubMed record.

8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

aimsTo assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.

resultsThe two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05). Second-phase insulin secretion was significantly increased only in the 1.25 mg/day group vs. placebo. Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05). There was no significant treatment effect on glucose effectiveness or insulin sensitivity.

conclusionsFourteen weeks of treatment with liraglutide showed improvements in first- and second-phase insulin secretion, together with improvements in arginine-stimulated insulin secretion during hyperglycaemia.

Indexed as

C-PeptideDiabetes Mellitus, Type 2Drug Administration ScheduleFemaleGlucagon-Like Peptide 1HumansHypoglycemic AgentsIncretinsInsulin ResistanceIslets of LangerhansLiraglutideMaleMiddle AgedReceptors, GlucagonTreatment OutcomeC-PeptideGlucagon-Like Peptide 1Hypoglycemic AgentsIncretinsLiraglutideReceptors, Glucagon

Identifiers

PMID18201212
OpenAlexW2145924144

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.